Background: Antibiotics used to treat Clostridioides difficile infection (CDI) can predispose patients to recurrent CDI (rCDI). Gut microbiome restoration by fecal microbiota transplantation is recommended by multiple guidelines after ≥2 episodes of rCDI, with no guideline-recommended options to restore the microbiome earlier in the course of CDI. RBX2660 is a standardized, microbiota-based live biotherapeutic being […]

Background: Clostridioides difficile is an opportunistic pathogen that causes an estimated 500,000 infections per year in the United States. RBX2660, a standardized, microbiota-based live biotherapeutic, is being investigated as a treatment option for recurrent C. difficile infection (rCDI). RBX2660 has demonstrated consistent tolerability and efficacy in reducing rCDI across 6 clinical studies. We present a […]

Background: Diabetic ketoacidosis (DKA) remains one of the commonest causes of medical and intensive care unit hospitalisations. DKA is a preventable hospital admission which is associated with multiple modifiable risk factors. However, little is known about factors that can predict healthcare resource utilisation in DKA. Previous studies have explored clinical and biochemical factors affecting the […]